<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="141180">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01830283</url>
  </required_header>
  <id_info>
    <org_study_id>BJCDPC-8</org_study_id>
    <nct_id>NCT01830283</nct_id>
  </id_info>
  <brief_title>The Safety, Immunogenicity and Immune Effect Research of the Varicella Vaccine After the 2nd Dose Vaccination</brief_title>
  <official_title>Phase 4 Study of the Varicella Vaccine After the 2nd Dose Vaccination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Center for Disease Control and Prevention</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the safety, immunogenicity and immune effect of the Varicella vaccine after
      the 2nd dose vaccination in Chao yang district, Bei jing, since the 2nd varicella
      vaccination was promoted by Beijing Center for Disease Control and Prevention in November,
      2012.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      &quot;Breakthrough&quot; varicella cases and varicella cases were monitored to evaluate the protective
      effective in a large population.

      Make the basic evaluation of safety for the two dose of varicella vaccination

      Monitoring the Varicella virus origin and virus types from illness cases in Chao yang
      district

      Make the evaluation of healthy costs reduce for the varicella emergency vaccination after
      large number of varicella cases occurred.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Incidence of varicella after 2 dose vaccination</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Detection the Varicella virus origin and virus types from illness cases in Chao yang district</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse event rate of varicella vaccine after 2 dose injection</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse event rate of varicella vaccine after 2 dose injection</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Antibody titre of varicella vaccine after 2 dose injection</measure>
    <time_frame>6 monthes</time_frame>
    <safety_issue>No</safety_issue>
    <description>Antibody titre of varicella vaccine after 2 dose injection</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50000</enrollment>
  <condition>Varicella</condition>
  <arm_group>
    <arm_group_label>1 dose varicella vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The providers would get the 2nd dose since they had one dose varicella vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 dose varicella vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The provider never get the varicella vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>varicella vaccine</intervention_name>
    <description>The providers would get varicella vaccine</description>
    <arm_group_label>1 dose varicella vaccine</arm_group_label>
    <arm_group_label>2 dose varicella vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants were between 4-12 years old

          -  Participants were in good healthy determined through medical history, physical
             examination, clinical judgment of the investor

        Exclusion Criteria:

          -  Having a fever (axillary temperature ＞37.0℃) before enrollment;

          -  Having a disease history of seizures, brain and mental disease and the vaccination
             history of allergies and convulsions;

          -  Antibiotics allergy;

          -  Having a problem of intramuscular injection because thrombocytopenia or other blood
             coagulation disorder;

          -  Having immunodeficiency or under immunosuppression therapy, radiation therapy;

          -  Having respiratory diseases, acute infection, chronic disease and HIV infection;

          -  Having systemic skin rash, skin tinea, herpes;

          -  Chronic liver and kidney disease;

          -  Heart disease, and severe hypertension;

          -  Have received whole blood, plasma or immunoglobulin therapy 3 months before
             enrollment;

          -  Have not received other vaccination in 7 days before enrollment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nianmin Shi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Chaoyang District Centers for Disease Control and Prevention</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Chaoyang District Centers for Disease Control and Prevention</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>May 27, 2013</lastchanged_date>
  <firstreceived_date>April 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Chickenpox</mesh_term>
    <mesh_term>Herpes Zoster</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
